tiprankstipranks
Trending News
More News >

Cidara Therapeutics Suspends ATM Prospectus with Jefferies

Story Highlights
Cidara Therapeutics Suspends ATM Prospectus with Jefferies

Don’t Miss TipRanks’ Half-Year Sale

Cidara Therapeutics ( (CDTX) ) has issued an update.

On June 24, 2025, Cidara Therapeutics announced the suspension and termination of its ATM Prospectus related to common stock sales under its agreement with Jefferies LLC. The company will halt stock sales until a new prospectus is filed, though the sales agreement itself remains active, indicating a strategic pause rather than a complete cessation of stock activities.

The most recent analyst rating on (CDTX) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Cidara Therapeutics stock, see the CDTX Stock Forecast page.

Spark’s Take on CDTX Stock

According to Spark, TipRanks’ AI Analyst, CDTX is a Neutral.

Cidara Therapeutics’ stock score is primarily hindered by its financial performance, marked by substantial losses and reliance on external financing. However, strong technical indicators and positive corporate events provide some optimism for future growth. The earnings call and valuation concerns, such as a negative P/E ratio, further temper the overall score.

To see Spark’s full report on CDTX stock, click here.

More about Cidara Therapeutics

Cidara Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of anti-infectives and immunotherapies.

Average Trading Volume: 275,533

Technical Sentiment Signal: Hold

Current Market Cap: $272.6M

See more insights into CDTX stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1